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Platelets are critical to hemostatic and immunological function, and are key players
in cancer progression, metastasis, and cancer-related thrombosis. Platelets interact
with immune cells to stimulate anti-tumor responses and can be activated by immune
cells and tumor cells. Platelet activation can lead to complex interactions between
platelets and tumor cells. Platelets facilitate cancer progression and metastasis by: (1)
forming aggregates with tumor cells; (2) inducing tumor growth, epithelial-mesenchymal
transition, and invasion; (3) shielding circulating tumor cells from immune surveillance
and killing; (4) facilitating tethering and arrest of circulating tumor cells; and (5) promoting
angiogenesis and tumor cell establishment at distant sites. Tumor cell-activated platelets
also predispose cancer patients to thrombotic events. Tumor cells and tumor-derived
microparticles lead to thrombosis by secreting procoagulant factors, resulting in platelet
activation and clotting. Platelets play a critical role in cancer progression and thrombosis,
and markers of platelet-tumor cell interaction are candidates as biomarkers for cancer
progression and thrombosis risk.
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INTRODUCTION
Platelets were first described as an independent cell type present in the blood in 1881 by Giulio
Bizzozero (reviewed in Mazzarello et al., 2001). They were named after their morphology in the
non-activated state, small discoid cells resembling “small plates.” Bizzozero was also the first to
describe the morphological changes in platelets attributed to platelet activation and their important
role in thrombus formation (Bizzozero, 1881). Subsequently, James Homer Wright described
platelets as originating from megakaryocytes in the bone marrow (Wright, 1910). Many bleeding
disorders and diseases attributed to defects in platelet function were described during this period.
Platelets are produced by hematopoietic stem cells in the liver during fetal development and
can be seen in fetal circulation as early as 8–9 weeks (Palis and Segel, 2016). Platelets quickly
reach adult quantities, and neonatal thrombocytopenia is defined by the same criteria as adult
thrombocytopenia (<150 × 109/L) (Sola-Visner, 2012). Late in gestation through adulthood,
platelet production shifts to megakaryocytes (MKs) in the bone marrow. Once mature, MKs
migrate to the vascular bed and release proplatelets into the circulation, eventually leading to the
dissolution of the entire MK (Machlus and Italiano, 2013). Once in circulation, proplatelets break
apart and form mature platelets that travel through the circulation for 7–10 days before being
cleared by resident phagocytes in the liver and spleen (Sørensen et al., 2009).
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Platelet Composition
Platelets possess and display a variety of functional
immunoreceptors that respond to a broad spectrum of agonists
including those associated with tissue injury and infection
(Kasirer-Friede et al., 2007; Cox et al., 2011). Platelets have
glycoproteins (GPs) that sense vascular and sub-endothelial
structures such as collagen and other exposed proteins, which
enable platelets to respond to injury. GPIbα and GPVI are
involved in thrombus formation (Gardiner and Andrews, 2014),
and GPIIb/IIIa, also known as integrin αIIbβ3, is critical for
platelet aggregation, adhesion to ECM, and clot retraction
(Kasirer-Friede et al., 2007). Platelets also express pattern
recognition receptors (PRRs) including toll-like receptors
(TLRs), NOD-like receptors (Zhang S. et al., 2015), and C-type
lectin receptors (Polgar et al., 1997). TLR expression enables
activated platelets to bind and capture bacteria (Cognasse et al.,
2005; Aslam et al., 2006). Other important surface receptors
including P-selectin (Furie et al., 2001), integrins (Kasirer-Friede
et al., 2007; Bennett et al., 2009), and FcγRIIa (Berlacher
et al., 2013) also increase upon platelet activation, facilitating
interactions between activated platelets and leukocytes.
Platelets are continually exposed to all components of plasma
through their open canalicular system, which provides a conduit
for release of granule contents, and facilitates platelet shape
change in response to stimuli (Escolar et al., 1989; Escolar and
White, 1991; Jurk and Kehrel, 2005). Mature platelets possess
three distinct types of cytoplasmic storage compartments: alpha
(α-) granules, dense (δ-) granules, and lysosomal (λ-) granules.
These granules contain vast array of bioactive molecules with
hemostatic and host defense properties that can be released
into the circulation or translocated to the platelet surface
upon platelet activation. α-granules are the most abundant type
and contain bioactive mediators including adhesion molecules,
coagulation factors, growth factors, cytokines and chemokines,
and microbicidal proteins. δ-granules store bioactive amines
(histamine and serotonin), ions (calcium and phosphate), and
nucleotides (ADP and ATP) (Yeaman, 2014). The list of proteins
housed in each type of granules is summarized in our previous
report (Ali et al., 2015).
Platelets are anucleate, but they contain thousands of unique
RNA transcripts (Zimmerman and Weyrich, 2008), including
long-lived mRNA that can act as a template for protein
translation throughout the platelet lifespan (Booyse and Rafelson,
1967) and unspliced pre-mRNA that can be processed by
megakaryocyte-derived spliceosome (Denis et al., 2005). In
addition to translation mechanisms common to many cell types,
platelet activation influences translation via mTOR signaling
(Weyrich et al., 1998). The 5′ and especially 3′ untranslated
regions of platelet mRNA contribute to differential translation
and transcript half-life (Zimmerman and Weyrich, 2008), and
activated-platelet protein-1 expressed during platelet activation
binds poly A sequences in the 3′ region to regulate translation
(Houng et al., 1997). Notably, platelet activation stimulates
translation of multiple proteins (Denis et al., 2005) including Bcl-
3 (Weyrich et al., 1998), tissue factor (Schwertz et al., 2006), and
IL-1β (Lindemann et al., 2001), among many others.
In addition to mRNA, platelets also contain microRNAs
(miRNAs). miRNAs are small non-coding RNAs shown to play
important roles in gene regulation, and act as biomarkers and
regulators of disease states (Ardekani and Naeini, 2010; Li and
Kowdley, 2012; McManus and Freedman, 2015). Platelets possess
the machinery necessary for processing pre-miRNA to functional
miRNA (Landry et al., 2009). Platelets contain a distinct miRNA
profile and changes to miRNA within the platelet can lead to
dysfunctional platelet activity (Plé et al., 2012; Rowley et al.,
2016). Platelet miRNA can also exert effects on surrounding
tissues, leading to decreased expression of intercellular adhesion
molecule-1 (ICAM-1) on the endothelium during myocardial
infarction (Gidlöf et al., 2013). As they are abundant in the
circulation and are able to secrete bioactive miRNA that can
affect surrounding cells and tissues, platelets’ role in regulation
of health and disease can be significant.
Platelet Function
Platelets play a critical role in hemostasis and immunity, and are
among the first cells to detect endothelial injury and microbial
pathogens invading the bloodstream and tissues (Al Dieri
et al., 2012; Gardiner and Andrews, 2013). Platelets circulate
in a quiescent state without forming stable adhesions with the
endothelial cells. Vascular injury causes platelet glycoproteins
GPVI and GPIbα to interact with exposed collagen and von
Willebrand Factor (VWF), respectively, in the subendothelial
matrix. These receptor-ligand interactions mediate platelets’
stable adhesion to the endothelial cells and initiate a cascade of
intracellular responses that results in amplification of activation
signals through the release of platelet agonists like ADP and
thrombin. In response to activation, platelets change their
shape, degranulate, and upregulate surface receptor expression.
Collectively, this leads to further platelet aggregation and
recruitment to the sites of tissue damage or infection (Semple
et al., 2011). In addition to activation by classic platelet agonists,
platelets can also be partially activated or “primed” by the
presence of atypical agonists such as IgG (Antczak et al., 2010).
Human platelets possess the Fcγ receptor IIa that is actively
able to bind and internalize IgG complexes (Worth et al., 2006;
Antczak et al., 2011). Pre-stimulation with IgG complexes leads
to increased activation in response to lower levels of agonists
causing a state of “platelet hypersensitivity” (Berlacher et al.,
2013). We have shown this phenomenon in systemic lupus
erythematosus (SLE), an inflammatory condition that is known
to have circulating IgG complexes.
PLATELET INTERACTION WITH IMMUNE
CELLS WITH RESPECT TO CANCER
Platelets play a role in inflammation by binding to immune
cells to modulate immune function. Binding of activated
platelets to leukocytes stimulates cytokine release, oxidative
burst, phagocytosis, and formation of neutrophil extracellular
traps (NETs), which are composed of DNA, histones, and
antimicrobial proteins (Kral et al., 2016). Platelets also recruit
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and activate macrophages and neutrophils in tumor tissue,
stimulating TGF-β release and platelet-tumor cell aggregation
(Kim and Bae, 2016). Macrophages infiltrate tumors and release
cytolytic factors including tumor necrosis factor α (TNF-α)
to destroy the tumor (Larrick and Wright, 1990), and it was
found that platelets reduced macrophage-mediated cytotoxicity
in fibrosarcoma by inhibiting the effects of TNF-α (Philippe et al.,
1993). Immune cells may also stimulate platelets. For example,
neutrophil release of myeloperoxidase partially activates platelets
(Kolarova et al., 2013). Moreover, NETs stimulate the intrinsic
pathway of the coagulation cascade, ultimately generating
thrombin and activating platelets (Gould et al., 2014).
Platelet-immune cell interactions have applications in cancer
treatment. For example, elevated PLR correlated with elevated
CA 19-9, the current biomarker used of diagnosis of pancreatic
cancer (Miglani et al., 2013). Similar changes in PLR have also
been reported in patients at risk of lung cancer (Sanchez-Salcedo
et al., 2016). Therefore, changes in PLR are most likely not
cancer-specific and may not be able to differentiate specific
cancer types based solely on PLR levels. However, elevated PLR
is reported as a prognostic tool (Zhou et al., 2014; Cummings
et al., 2015; Messager et al., 2015; Zhang Y. et al., 2015; Wang
et al., 2016) and staging and follow up tool (Emir et al., 2015;
Jia et al., 2015), often in conjunction with neutrophil/lymphocyte
ratio (NLR). Furthermore, PLR has been found to be an
independent predictor of venous thromboembolism in cancer
patients (Ferroni et al., 2015). COmbination of Platelet count
andNeutrophil to Lymphocyte Ratio (COP-NLR) (Ishizuka et al.,
2013, 2014; Feng et al., 2014a; Zhang H. et al., 2015; Nakahira
et al., 2016) and Neutrophil-Platelet Score (NPS) (Watt et al.,
2015) are predictors of survival for several types of cancer.
Notably, some scoring systems that include evaluation of platelet
count or function have higher predictive value in certain cancers
than tools not analyzing platelets (Feng et al., 2014b; Ferroni et al.,
2015; Sanchez-Salcedo et al., 2016), indicating that platelets may
play a key role in cancer development and have prognostic value.
PLATELETS AND CANCER PROGRESSION
Platelet-Tumor Cell Interaction
Platelets play an integral role in the development and metastasis
of cancer; high platelet counts have been linked to increased
metastasis (Buergy et al., 2012) and poorer outcomes in multiple
types of cancer (Kim et al., 2014, 2015; Moschini et al., 2014;
Voutsadakis, 2014; Chadha et al., 2015; Ji et al., 2015). Tumor
cells interact with platelets through a number of receptors and
signaling molecules. For example, tumor cells release soluble
molecules that activate platelets, including ADP and thrombin
(Zucchella et al., 1989; Boukerche et al., 1994; Bambace and
Holmes, 2011) while direct contact of platelets with tumor cells
also results in activation (Suzuki-Inoue et al., 2006; Erpenbeck
and Schon, 2010; Lal et al., 2013; Menter et al., 2014; Li,
2016). Platelet-tumor cell aggregates form through binding of
platelet integrin αIIbβ3 to tumor cell integrin αvβ3 via RGD-
containing proteins including fibrinogen, von Willebrand factor,
and fibronectin (Kitagawa et al., 1989; Felding-Habermann
et al., 1996), a process known as tumor cell-induced platelet
aggregation (TCIPA) (Jurasz et al., 2004; Goubran et al., 2013).
electins expressed on platelets, leukocytes, and endothelium
may also bind tumor cells to form platelet-tumor-leukocyte
aggregates (Laubli and Borsig, 2010). Specifically, P-selectin
expressed on the surface of activated platelets binds to many
types of human cancer cells (Chen and Geng, 2006). Activated
platelets were observed to interact with small cell lung cancer
and neuroblastoma cell lines, and this interaction was blocked
with inhibitory anti-P-selectin antibodies (Stone and Wagner,
1993), indicating that P-selectin is a key mediator of platelet-
tumor interaction (Borsig, 2008). L-selectin on leukocytes
acts synergistically with P-selectin, facilitating platelet-tumor
interaction (Borsig et al., 2002). Podocalyxin-like protein 1
(PCLP1) binds E- and L-selectin in pancreatic cancer (Dallas
et al., 2012), and is overexpressed in many cancers and on
activated platelets (Amo et al., 2014). Once activated, platelets
can then bind to tumor cells via P-selectin (Chen and Geng,
2006; Coupland et al., 2012; Qi et al., 2015) and glycoproteins
(Lonsdorf et al., 2012; Goubran et al., 2013) and directly induce
tumor growth and metastasis by releasing pro-tumor angiogenic
and growth factors.
Platelet-derived microparticles (PDMPs) also promote
metastasis and angiogenesis by producing matrix
metalloproteinase 2 (MMP-2), angiogenic platelet-derived
growth factors and tissue factor (Dashevsky et al., 2009; Martinez
and Andriantsitohaina, 2011; Falanga et al., 2012; Varon et al.,
2012). These pathways create a loop of activation as tumor cells
activate platelets, which in turn support growth, invasion, and
metastasis of tumor cells (Goubran et al., 2013).
Tumor cells transfer RNA into platelets via microvesicles,
resulting in tumor educated platelets (TEPs) (Nilsson et al.,
2011). Importantly, this observation was applied to cancer
diagnostics using mRNA sequencing of TEPs. Sequencing of
TEPs was 96% accurate in distinguishing cancer patients from
individuals without cancer, and was able to provide information
about the location of some cancers (Best et al., 2015). Platelet
mRNA profiles showed downregulation of numerous genes,
including many associated with translation, IL-signaling, protein
synthesis, and immunity, and upregulation of cancer-associated,
metabolic, cytoskeletal, and platelet-related genes (Best et al.,
2015). EML4-ALK rearrangements in non-small-cell lung cancer
were detectable by RT-PCR in platelets, and this correlated with
poor prognosis (Nilsson et al., 2015), suggesting TEP may be a
promising source for liquid biopsy (Feller and Lewitzky, 2016;
Perez-Callejo et al., 2016).
Platelet Effect on Tumor Invasion and
Intravasation
Activated platelets play multiple roles in the progression of
tumor metastasis, including facilitation of tumor cell epithelial-
mesenchymal transition (EMT), degradation of surrounding
extracellular matrix (ECM), increasing vascular permeability,
and aiding in the establishment of malignancies in distant tissues
(Miyashita et al., 2015; Pang et al., 2015; Guillem-Llobat et al.,
2016) through interactions with tumor cells through selectins
and glycoproteins (Kohler et al., 2010; Laubli and Borsig, 2010;
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Gay and Felding-Habermann, 2011; Bendas and Borsig, 2012;
Pang et al., 2015). Activated platelets promote metastasis by
secreting lysophosphatidic acid (LPA), a lipid that has growth
factor-like properties, which has been found to be involved in
the progression of multiple cancers (Mills and Moolenaar, 2003;
Leblanc and Peyruchaud, 2015; Lou et al., 2015). LPA plays a role
in many cellular processes including cell proliferation, survival,
migration, tumor cell invasion, and reversal of differentiation
through multiple G protein-coupled receptor (LPA1-6) cascades,
and is a potential target for cancer therapy (summarized in
Mills and Moolenaar, 2003). Activated platelets also secrete
transforming growth factor β (TGF-β) (Assoian and Sporn, 1986)
and platelet-derived growth factor (PDGF) (Kong et al., 2008)
from α-granules in response to tumor cell stimulation, inducing
EMT (Assoian and Sporn, 1983; Radisky and LaBarge, 2008;
Labelle et al., 2011; Yu et al., 2013; Leblanc and Peyruchaud,
2016). By releasing TGF-β and PGE2, platelets strongly activate
genes promoting EMT, ECM remodeling, and metastasis in
tumor cells (Labelle et al., 2011; Guillem-Llobat et al., 2016).
Tumor cell expression of the EMT-associated transcription factor
Snail1 correlated with platelet localization on the leading edge of
tumor cells as indicated by CD42b (Miyashita et al., 2015). This
is an important area of investigation that may yield important
results.
Platelets also influence tumor metastasis by enhancing tumor
cell expression of tissue factor, a primary initiator of the
coagulation cascade (Orellana et al., 2015). Tissue factor is
constitutively present on the surface of malignant tumors which
activates platelets (Callander et al., 1992; Date et al., 2013), and
is shed on tumor microvesicles (Yu and Rak, 2004). Tissue
factor generates thrombin, which has been shown to induce
platelet-tumor cell interactions in vitro, and administration of
thrombin increases pulmonary metastases in murine models
of colon cancer (summarized in Gay and Felding-Habermann,
2011). Tissue factor also drives growth of primary tumors,
stimulates angiogenesis, and is associated with EMT and cancer
stem cell behavior (Versteeg, 2015), and was found to be an
indicator of metastasis and prognosis in numerous types of
cancer (summarized in van den Berg et al., 2012).
Once tumor cells undergo EMT, the next step in metastasis
is to invade local tissues and enter the bloodstream (Hunter
et al., 2008). Tumor cells activate platelets through a number
of mechanisms, including release of platelet-activating soluble
factors like ADP and thrombin and ligation of TLR-4 (Grignani
et al., 1989; Li, 2016). Activated platelets then release serotonin,
ATP and histamine increasing vascular permeability, and MMPs
that degrade ECM (Deryugina and Quigley, 2006; Li, 2016).
Platelet-derived LPA also up-regulates matrix metalloproteinase
(MMP) activity (Lou et al., 2015). The weakened extracellular
matrix and endothelial barrier allow tumor cells to enter
circulation and metastasize (Stegner et al., 2014).
Tumor Shielding
Tumor cells free in circulation are susceptible to immune
surveillance and killing. Natural killer (NK) cells are the primary
killers of metastasizing tumor cells (Talmadge et al., 1980;
Wiltrout et al., 1985). Platelets shield tumor cells from NK
cell lysis by forming aggregates on the tumor cell surface
(Nieswandt et al., 1999). Platelets interfere with NK cell binding
to tumor cells both sterically and by inhibiting NK cell cytolytic
function (Philippe et al., 1993; Shau et al., 1993). Specifically,
activated platelets release soluble factors (e.g., TGF-β) that
down-regulate NK cell immunoreceptors and inhibit NK cell
functions including IFN-γ production, cytotoxicity, and granule
mobilization (Kopp et al., 2009).
Platelets also may facilitate tumor escape from NK cell lysis by
modulating expression of major histone compatibility complex
(MHC) class I. MHC class I is an antigen that host cells express
to identify them as “self ” or to present antigen fragments to
CD8+ T cells if the host cell is infected or abnormal. Many types
of malignancies have been shown to express abnormal MHC
class I, including MHC class I with structurally altered heavy
chains, mutated β2-microglobulin and TAP1, or dysregulated
antigen processingmachinery, leading to reduced or absentMHC
class I expression (Seliger, 2008, 2014). This dysregulation makes
tumor cells susceptible to killing by NK cells, which target cells
lacking MHC class I (Seliger, 2008). Platelets can transfer MHC
class I antigens to tumor cells, protecting them from T-cell
mediated immunity without inducing NK cell cytotoxicity and
IFN-γ production (Placke et al., 2011, 2012), and direct platelet
inhibition of tumor cell lysis by NK cells can also occur in an
MHC-independent manner (Nieswandt et al., 1999). In mice,
thrombocytopenia inhibits metastasis but this effect is reversed if
NK cells are depleted, indicating platelets’ key role in metastasis
is shielding tumor cells from NK cell killing (Kopp et al., 2009).
Platelets and platelet-derived microparticles adhere to tumor
cells through interactions with integrins and selectins (Kitagawa
et al., 1989; Felding-Habermann et al., 1996; Gay and Felding-
Habermann, 2011). Additionally, fibronectin and other adhesive
molecules may act as a bridge between platelets and tumor
cells, as mediated by PCLP1 (Amo et al., 2014). Tumor cells are
enshrouded in platelet-fibrin mesh, shielding them from NK cell
contact and immune surveillance in circulation (Borsig et al.,
2001).
Platelet Effect on Tumor Cell Arrest and
Extravasation
Platelets and platelet-derived microparticles adhered to
circulating tumor cells also facilitate tethering and arrest (Honn
et al., 1992; Gay and Felding-Habermann, 2011; Menter et al.,
2014; Li, 2016). Platelets were found to act as chemoattractants
for circulating tumor cells, potentially aiding in tumor cell
homing and establishment of metastatic sites (Orellana et al.,
2015). Tumor cell-activated platelets release ATP, which binds
P2Y2 receptors on the endothelium, opening the transendothelial
barrier and allowing tumor cells to exit the bloodstream into
metastatic sites (Schumacher et al., 2013). LPA, TGFβ, MMP,
PGE2, and other platelet- and leukocyte-derived factors that
assisted in EMT and intravasation weaken the endothelium and
also facilitate extravasation (Stegner et al., 2014). Platelet-bound
tumor cells may bind directly to selectins on the endothelium,
leading to tethering, rolling, and ultimately extravasation
(Bendas and Borsig, 2012; Coupland et al., 2012). Myeloid
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cells can facilitate this process by activating the endothelium
through interleukin (IL)-1α, IL-1β, and TNF-α (Labelle and
Hynes, 2012). Tumor cells may also be slowed due to their
large size upon reaching microvasculature, among other
mechanisms (summarized in Witz, 2008). Notably, the pro-
coagulant characteristics of platelet-tumor aggregates facilitate
the formation of microthrombi in small vessels, further slowing
tumor cell migration and enhancing arrest rate (Menter et al.,
2014).
Platelet Effect on Tumor Cell
Establishment and Angiogenesis
Tumor cells do not necessarily remain and grow at the
initial site of arrest; many cells die or become dislodged,
and some cells have been observed to leave and reattach at
another site (Kienast et al., 2010). Successful metastasis requires
extravasation close to sufficient vasculature to allow tumor cells
to obtain nutrients (Folkman, 1971) and recruit leukocytes
to form premetastatic niches (Labelle and Hynes, 2012).
Premetastatic niche formation depends on communication with
the microenvironment (LaBarge et al., 2007; LaBarge, 2010),
including platelet-derived TGF-β and P2Y12 signaling (Labelle
et al., 2011;Wang et al., 2013). TGF-β reduces the effect of tumor-
entrained neutrophils (TEN; a subset of CD11b+Ly-6GH+MMP-
9+ cells not present in healthy individuals) (Fridlender et al.,
2009), which typically kill tumor cells by producing hydrogen
peroxide (Granot et al., 2011).
Platelet-activated tumor cells have enhanced expression of
pro-metastatic genes including proteases, cytokines, and growth
factors to facilitate invasion and metastatic seeding (Labelle
et al., 2011). Among other pro-angiogenic factors (summarized
in Sabrkhany et al., 2011), platelets are a primary source of
vascular endothelial growth factor (VEGF), a growth factor
that increases vascular permeability, promotes extravasation, and
is critical for angiogenesis (Verheul et al., 1997; Sierko and
Wojtukiewicz, 2004). Platelets activated by TF present on the
surface of endothelial cells (Shoji et al., 1998; Verheul et al.,
2000) release VEGF in malignant tissue, directly promoting
angiogenesis (Verheul et al., 2000). Tumor-derived thrombin
also plays an angiogenic role, inducing endothelial cell growth
(Herbert et al., 1994) and increasing platelet release of VEGF.
Platelets are thought to contain angiogenesis stimulators and
inhibitors secreted based on stimulation of proteinase activated
receptors (PARs). Some studies show angiogenesis stimulators
and inhibitors are differentially released in response to selective
PAR agonists to regulate angiogenesis (Ma et al., 2005; Italiano
et al., 2008). However, kinetic analysis revealed no functional
pattern in α-granule release, and both types of releasates were
ultimately shown to stimulate angiogenesis in vitro and in vivo
(Jonnalagadda et al., 2012; Huang et al., 2015).
Platelet microparticles also promote angiogenesis (Martinez
and Andriantsitohaina, 2011), stimulating the formation
of capillary tube and network formation (Kim et al., 2004;
Prokopi et al., 2009) and stimulating tumor cell expression
of pro-angiogenic factors (Janowska-Wieczorek et al.,
2005). Microparticles in cancer patients also express tissue
factor (Hron et al., 2007), further activating platelets and
stimulating the angiogenic cascade to support metastatic tumor
growth.
CANCER AND COAGULATION
The presence of tumor cell-activated platelets in the bloodstream
may predispose cancer patients to thrombotic events. The
correlation between cancer and risk of venous thromboembolism
(VTE), first noted in 1865 by Dr. Armand Trousseau, has
been well-documented (Varki, 2007). A 2007 study found that
cancer patients on chemotherapy were 47 times more likely
to experience VTE (Khorana et al., 2007). In general, active
cancer increases risk for VTE by four- to seven-fold, and
cancer-associated VTE is on the rise (Key et al., 2016). Cancer
patients with elevated pre-chemotherapy platelet counts were
significantly associated with VTE, indicating that platelets likely
play a role in the development of thrombotic events (Khorana
et al., 2005; Kadlec et al., 2014).
Tumor cells stimulate clotting and thrombosis through
multiple mechanisms (Mackman, 2008). Tissue factor produced
by tumor cells and tumor-derived microparticles stimulates
the coagulation cascade (Owens and Mackman, 2011; Menter
et al., 2014; Phillips et al., 2015), activating platelets and
promoting thrombosis via the tissue factor (extrinsic) pathway
(Mackman, 2008). Indeed, plasma tissue factor was found to be
predictive of VTE in pancreatic cancer (Khorana et al., 2008).
Activated platelets and negatively-charged phospholipids shed
by tumor cells may also stimulate coagulation via the contact
activation (intrinsic) pathway (Dicke and Langer, 2015; Key et al.,
2016). Tumor-derived IL-6 and hepatic thrombopoietin were
also associated with thrombocytosis and thrombosis (Hisada
et al., 2015). Additionally, tumor-derived microparticles have
strong procoagulant activity and are associated with VTE in
cancer (Manly et al., 2010; Geddings and Mackman, 2013;
Mege et al., 2016). These microparticles were found to activate
platelets and induce aggregation and thrombus formation,
and accumulated in the thrombus by interacting with P-
selectin (Thomas et al., 2009), demonstrating the integral
role platelets play in the development of cancer-associated
VTE.
VTE and thrombocytosis are factors associated with poor
prognosis for patients with cancer (Sorensen et al., 2000; Kourelis
et al., 2014; Chadha et al., 2015; Chen et al., 2015), highlighting
the need for a method to quantify VTE risk in cancer patients.
Markers of platelet-tumor cell interaction including P-selectin,
tissue factor, and microparticles are candidates to detect early
signs of VTE, as are markers of inflammation (C-reactive
protein) and coagulation (D-dimer, Factor VIII; summarized in
Hanna et al., 2013). Early detection of risk factors associated
with VTE may influence use of thromboprophylaxis, and may
substantially reduce morbidity and mortality in cancer patients.
Given their critical role in tumor growth, metastasis, and cancer-
associated thrombosis, markers of platelet activity should be
explored as biomarkers and potential therapeutic targets for
cancer progression and VTE.
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Platelets play a critical role in cancer progression and
metastasis, and contribute to the development of VTE in cancer.
However, it is not yet clear whether platelet activation and
thrombocytosis are ultimately the causative agent or the result
of tumor progression. Additionally, the molecular mechanism
behind platelet-induced coagulation in cancer has yet to be
described. As research continues to utilize platelet biomarkers in
cancer diagnosis, prognosis, and risk, much will be discovered
about the platelet-cancer dynamic on a mechanistic level.
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